Conflict of interests
In the past 3 years, SL declares having received research grants from Astra Zeneca and Santelys, remunerations for symposiums by Sanofi and Novartis.
FA declares personal fees for consulting, lectures or boards from Stallergenes Greer, ALK, AImmune Therapeutics, GSK, Novartis, and Sanofi.
AD declares consultancy or speaker fees from Novartis, GSK, Sanofi, Regeneron, AstraZeneca, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science, ALK, Stallergènes-Greer outside the submitted work.
GL declares remunerations for symposia from DBV Technologies, Aimmune Therapeutics, for conferences from Novartis Pharma, Astra Zeneca, ALK, board consulting for ALK, Stallergenes-Greer, Aimmune Therapeutics, advices for Meenuts, expert consulting for ALK, Stallergenes-Greer.